SGLT2 inhibitors × glycemic control

TrialThe lancet. Diabetes & endocrinology2014

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.

Martin Ridderstråle et al.PubMed ↗Publisher ↗

What the trial testedas reported · 1,549 people · 2014

Not counted

Lowered glycemic control

−0.11percentage points−0.19 to −0.02

As reported

difference −0.11 %, 95% CI −0.19 to −0.02

One number in the abstract

the abstract, start to end

empagliflozin versus glimepiride was -0.11% (95% CI -0.19 to -0.02;

← favours treatmentfavours comparator →
could be chance
Glycemic control
−0.11−0.19 to −0.02
SGLT2 inhibitorsSulfonylureas & glinidesGlycemic control
1 / 3

180 papers cite itlatest 60 shown

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

4 trials

Full record →Abstract, authors, funding and every citing paper · PMID 24948511